Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Jul;49(1):42-6.
doi: 10.1136/gut.49.1.42.

Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease

J F Colombel  1 , P Rutgeerts, H Malchow, M Jacyna, O H Nielsen, J Rask-Madsen, S Van Deventer, A Ferguson, P Desreumaux, A Forbes, K Geboes, L Melani, M Cohard
Affiliations
Clinical Trial

Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease

J F Colombel et al. Gut. 2001 Jul.

Abstract

Background and aims: New lesions of Crohn's disease occur early after ileal or ileocolonic resection and ileocolonic anastomosis. We performed a double blind controlled trial to evaluate the safety and tolerance of recombinant human interleukin 10 (IL-10; Tenovil) in subjects operated on for Crohn's disease. We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery.

Methods: Patients with Crohn's disease who underwent curative ileal or ileocolonic resection and primary anastomosis were randomised within two weeks after surgery to receive subcutaneous Tenovil 4 microg/kg once daily (QD) (n=22) or 8 microg/kg twice weekly (TIW) (n=21), or placebo (QD or TIW) (n=22). An ileocolonoscopy was performed after 12 weeks of treatment.

Results: Compliance was excellent. The most frequently observed adverse events were mild and moderate in severity and equally distributed across treatment groups. Thirty seven patients in the pooled Tenovil group and 21 patients in the pooled placebo group were evaluable by endoscopy. At 12 weeks, 11 of 21 patients (52%) in the placebo group had recurrent lesions compared with 17 of 37 patients (46%) in the Tenovil group (ns). The incidence of severe endoscopic recurrence was similar in both groups (9%).

Conclusion: Tenovil treatment for 12 consecutive weeks in patients with Crohn's disease after intestinal resection was safe and well tolerated. No evidence of prevention of endoscopic recurrence of Crohn's disease by Tenovil was observed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean haemoglobin concentrations in the Tenovil (SCH 52000) 4 µg/kg once daily (QD) and 8 µg/kg twice weekly (TIW) treatment groups and in the pooled placebo group during the treatment and follow up phases of the study.
Figure 2
Figure 2
Ileal concentrations of interleukin 10 (IL-10) mRNA at surgery.
See this image and copyright information in PMC

References

    1. Gastroenterology. 2000 Feb;118(2):264-73 - PubMed
    1. Gastroenterology. 1998 Feb;114(2):262-7 - PubMed
    1. Gut. 1984 Jun;25(6):665-72 - PubMed
    1. Gastroenterology. 1998 Jul;115(1):182-205 - PubMed
    1. Gastroenterology. 1998 Aug;115(2):259-67 - PubMed

Publication types

MeSH terms